Editors' Note: This article covers stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
Tonix Pharmaceuticals (TNXP), which is developing a sublingual formulation of cyclobenzaprine known as TNX-102 SL for use in fibromyalgia and post-traumatic stress disorder, has enjoyed a powerful rally (partially catalyzed by an outstanding article by Joe Springer) with the stock rising from $8.50 to a peak of $21 in the past month. The entire investment thesis on TNXP lies in whether the pivotal phase 2b trial expecting results in October 2014 will succeed. In this article, I provide a digest of the medical literature relevant...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: